Drugs / ASTX029-01
last change Mar 2025 re-read 2 minutes ago

ASTX029-01

Developed for
acute myeloid leukemia
Investigated by
M.D. Anderson Cancer Center

Trials 1 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06113289 Feb 2024 → Mar 2025 acute myeloid leukemia M.D. Anderson Cancer Center Withdrawn No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ASTX029-01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06113289
Route Oral “Given by PO” NCT06113289